Quarterly report pursuant to Section 13 or 15(d)

Organization, Plan of Business Operations (Details)

v3.21.1
Organization, Plan of Business Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Feb. 08, 2019
Mar. 31, 2021
Dec. 31, 2020
Nov. 12, 2018
Cash and cash equivalents   $ 1,825 $ 3,132  
Contractual milestone payments   5,000    
Accumulated deficit   $ 74,266 $ 73,268  
Line of Credit [Member]        
Interim Financing Amount $ 7,000      
Invagen Pharmaceuticals Inc [Member]        
Percentage of equity interest agreed to acquire in first stage       33.30%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned       $ 35,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Remaining Purchase Amount       $ 180,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333      
Business Acquisition, Share Price $ 6.00      
Business acquisition shares acquisition for net proceeds $ 31,500      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 33.30%